CIP2A drives lung adenocarcinoma by activating mitochondrial respiratory complexes IV and V
Cancer Letters · 2026-11 · 218967
DOI: 10.1016/j.canlet.2026.218967 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-11. Verfasst von Fu-Ying Yang und 19 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Molecular Oncology & Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Canc…. Die Arbeit nennt 81 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Natural Science Foundation.
Abstract (Originalsprache)
To determine the cancer-initiating activity of oncoprotein CIP2A, which is overexpressed in a majority of cancers and promotes cell growth by stabilizing MYC, we established an alveolar type 2 cell-specific CIP2A transgenic mouse line. Among 114 transgenic mice aged 12 months or older, 23 (20.2%) developed lung adenocarcinoma (LUAD)-like disease, significantly higher than in the control mice (3/63, 4.8%). Multi-omic studies revealed enrichment of the oxidative phosphorylation (OXPHOS) pathway in tumor tissues from transgenic mice. CIP2A upregulated phosphorylation of FOXO3A (p-FOXO3A S253) by inhibiting phosphatase PP2A-B56α and promoted FOXO3A mitochondrial translocation. CIP2A-FOXO3A reshaped mitochondrial morphology, activated mitochondrial DNA transcription, and enhanced complexes IV/V activities. OXPHOS inhibitor repressed CIP2A-induced cell proliferation and tumor growth. Moreover, tobacco carcinogens upregulated CIP2A and p-FOXO3A S253 and significantly increased cancer incidence in CIP2A-transgenic mice. These data indicate that CIP2A plays a critical role in mitochondrial regulation and represents a promising therapeutic target for LUADs lacking actionable driver mutations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Molecular Oncology & Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medi…
- Department of Thoracic Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, Zhejiang Province, China.
- Department of Basic Medicine, Anhui Institute of Medicine, Hefei, 230601, Anhui Province, China.
- Institute of Cancer Research, Henan Academy of Innovations in Medical Sciences, Zhengzhou, 450000, Henan Province, China.
Förderung
- National Natural Science Foundation of China
- Beijing Natural Science Foundation
Zitieren
APA
Yang, F. Y., Wang, D., Ye, L., Zhang, Y. M., Liang, L. J., Zhang, Y. F., Tan, Y. S., Alifu, A., Lv, M. Y., Xie, F. R., Gao, Y. Y., Xu, J. J., Liu, Y. T., Wang, C., Xu, B. Q., Bai, Y. Z., Liao, Z. X., Liu, Y. T., Wang, G. Z., & Zhou, G. B. (2026). CIP2A drives lung adenocarcinoma by activating mitochondrial respiratory complexes IV and V. Cancer Letters, 218967. https://doi.org/10.1016/j.canlet.2026.218967
Vancouver
Yang FY, Wang D, Ye L, Zhang YM, Liang LJ, Zhang YF, et al. CIP2A drives lung adenocarcinoma by activating mitochondrial respiratory complexes IV and V. Cancer Letters. 2026:218967. doi:10.1016/j.canlet.2026.218967
BibTeX
@article{Yang2026,
author = {Yang, Fu-Ying and Wang, Di and Ye, Liu and Zhang, Yi-Meng and Liang, Li-Jun and Zhang, Yan-Fei and Tan, Yi-Shuai and Alifu, Aikede and Lv, Meng-Yao and Xie, Fen-Rong and Gao, Yan-Yun and Xu, Jiao-Jiao and Liu, Yang-Tong and Wang, Cong and Xu, Bing-Qing and Bai, Yan-Zhi and Liao, Zhi-Xiao and Liu, Yu-Tao and Wang, Gui-Zhen and Zhou, Guang-Biao},
title = {CIP2A drives lung adenocarcinoma by activating mitochondrial respiratory complexes IV and V},
journal = {Cancer Letters},
year = {2026},
pages = {218967},
doi = {10.1016/j.canlet.2026.218967}
}
EUVIMED